Editas Medicine, Inc. financial data

Symbol
EDIT on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
11 Hurley St., Cambridge, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 492 % -32%
Debt-to-equity 48 % +28.2%
Return On Equity -62.6 % -13.5%
Return On Assets -42.3 % -5.43%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 82.5M shares +1.03%
Common Stock, Shares, Outstanding 82.4M shares +1%
Entity Public Float 671M USD +5.89%
Common Stock, Value, Issued 8K USD 0%
Weighted Average Number of Shares Outstanding, Basic 82.3M shares +15.3%
Weighted Average Number of Shares Outstanding, Diluted 82.3M shares +15.3%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 67M USD +247%
Research and Development Expense 213M USD +32.4%
General and Administrative Expense 67M USD -10%
Operating Income (Loss) -213M USD +1.39%
Nonoperating Income (Expense) 19.6M USD +91.3%
Net Income (Loss) Attributable to Parent -193M USD +6%
Earnings Per Share, Basic -2.33 USD/shares +21.3%
Earnings Per Share, Diluted -2.33 USD/shares +21.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 64.4M USD -70.8%
Marketable Securities, Current 215M USD +1.67%
Assets, Current 286M USD -35.1%
Property, Plant and Equipment, Net 14.2M USD +10.2%
Operating Lease, Right-of-Use Asset 37M USD +6.15%
Other Assets, Noncurrent 8.15M USD +55.1%
Assets 385M USD -29%
Accounts Payable, Current 13.8M USD +70.7%
Employee-related Liabilities, Current 8.13M USD +26.8%
Accrued Liabilities, Current 27.7M USD -0.81%
Contract with Customer, Liability, Current 14.7M USD +78.6%
Liabilities, Current 74.3M USD +36.3%
Contract with Customer, Liability, Noncurrent 54.2M USD -10.7%
Operating Lease, Liability, Noncurrent 20.5M USD -23.6%
Other Liabilities, Noncurrent 3.77M USD
Liabilities 153M USD +7.57%
Accumulated Other Comprehensive Income (Loss), Net of Tax -442K USD +80.7%
Retained Earnings (Accumulated Deficit) -1.36B USD -16.6%
Stockholders' Equity Attributable to Parent 232M USD -42%
Liabilities and Equity 385M USD -29%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -49.9M USD -39.4%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities -4.75M USD -120%
Common Stock, Shares Authorized 195M shares 0%
Common Stock, Shares, Issued 82.4M shares +1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -54.4M USD -335%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 68.3M USD -69.6%
Deferred Tax Assets, Valuation Allowance 329M USD +11%
Deferred Tax Assets, Gross 338M USD +9.45%
Operating Lease, Liability 36.5M USD -16.9%
Depreciation 1.41M USD -8.74%
Payments to Acquire Property, Plant, and Equipment 1.87M USD +1.69%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -192M USD +6.39%
Lessee, Operating Lease, Liability, to be Paid 43.4M USD -19.6%
Property, Plant and Equipment, Gross 43.1M USD +18.7%
Operating Lease, Liability, Current 18.2M USD +76%
Lessee, Operating Lease, Liability, to be Paid, Year Two 8.39M USD -32.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 14.8M USD +2.02%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 6.91M USD -31.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 7.13M USD +0.08%
Deferred Tax Assets, Operating Loss Carryforwards 153M USD +5.88%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 13.7M USD +15.8%
Lessee, Operating Lease, Liability, to be Paid, Year Four 7.08M USD +2.11%
Operating Lease, Payments 3.85M USD -1.28%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 9.19M USD -26.8%
Share-based Payment Arrangement, Expense 22.7M USD +8.13%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%